Premium
Oncogenic properties of sphingosine kinases in haematological malignancies
Author(s) -
WallingtonBeddoe Craig T.,
Bradstock Kenneth F.,
Bendall Linda J.
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12302
Subject(s) - sphingosine , sphingosine 1 phosphate , sphingolipid , sphingosine kinase , kinase , cancer research , biology , sphingosine kinase 1 , cancer , lipid signaling , bioinformatics , microbiology and biotechnology , biochemistry , genetics , enzyme , receptor
Summary The sphingosine kinases ( S ph K s) have relatively recently been implicated in contributing to malignant cellular processes with particular interest in the oncogenic properties of SPHK 1. Whilst SPHK 1 has received considerable attention as a putative oncoprotein, SPHK 2 has been much more difficult to study, with often conflicting data surrounding its role in cancer. Initial studies focused on non‐haemopoietic malignancies, however a growing body of literature on the role of sphingolipid metabolism in haemopoietic malignancies is now emerging. This review provides an overview of the current state of knowledge of the S ph K s and the bioactive lipid sphingosine 1‐phosphate ( S 1 P ), the product of the reaction they catalyse. It then reviews the current literature regarding the roles of S 1 P and the S ph K s in haemopoietic malignancies and discusses the compounds currently available that modulate sphingolipid metabolism and their potential and shortcomings as therapeutic agents for the treatment of haematological malignancies.